Overview

Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

Status:
Terminated

Trial end date:
2016-09-06

Target enrollment:

Participant gender:

Summary

This is a correlative study to characterize serum metabolites associated with bone deposition, growth and turnover in patients with newly diagnosed metastatic CRPC who are not currently receiving bone targeting agents.

Phase:

Phase 2

Details

Lead Sponsor:

University of Hawaii

Treatments:

Denosumab
Prednisone